
Bayard L. Powell, MD
Advertisement
Articles by Bayard L. Powell, MD


Bayard L. Powell, MD, from the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses the treatment of older patients with acute myeloid leukemia (AML).

Bayard L. Powell, MD, the Director-At-Large and a Professor in Hematology & Oncology at the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses the next steps for CPI-613 in hematologic malignancies.

Bayard L. Powell, MD, from the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses a phase I study that explored the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies.
Advertisement
Latest Updated Articles
Dr. Powell Discusses CPI-613 in Hematologic MalignanciesJune 11th 2013
Dr. Powell Discusses the Next Steps for CPI-613July 25th 2013
Dr. Powell on the Treatment of Older Patients With AMLAugust 20th 2013
Dr. Powell on CPI-613, Cytarabine, Mitoxantrone Combo for AMLJanuary 9th 2015
Advertisement
Advertisement
Trending on OncLive
1
Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML
2
Ofirnoflast Elicits Durable Transfusion Independence, Hematologic Improvement in Lower-Risk MDS
3
ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML
4
DISC-3405 Reduces Phlebotomy Events and Controls Hematocrit in Polycythemia Vera
5
